PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 23, 2013
New Clinical Trial Partners to Expand Laboratory Sciences Clinical Sample Analysis Groups
Author(s)Pharmaceutical Technology Editors
Charles River has established partnerships with Target Health Inc. and Theorem Clinical Research Inc.
Advertisement
Charles River has established partnerships with Target Health Inc. and Theorem Clinical Research Inc. allow nonclinical testing programs performed by Charles River in bioanalysis, immunogenicity, and immunology to transition to support clinical trials.
Charles River develops and validates assays in support of nonclinical programs. Many of these assays can be transferred and validated for human matrix and subsequently used for analyzing clinical samples.
In a statement, the Charles River reports that these new relationships will allow company scientists to manage clinical sample analysis using defined processes and procedures to improve customer satisfaction.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement